Spinal Muscular Atrophy
By inhibiting the activation of myostatin, SRK-015 may promote a clinically meaningful increase in muscle mass and strength.
Improved motor function was observed among more participants in the nusinersen group compared with those in the control group.
Nusinersen improves motor function in children with later-onset spinal muscular atrophy: The CHERISH trialFebruary 15, 2018
Intrathecal injections of nusinersen in pediatric later-onset spinal muscular atrophy (SMA) patients were associated with increased clinical motor function scores compared to sham treated patients.
Because of the liver's prominent role in drug metabolism, clinicians should monitor patients' hepatic function.
Patients who received nusinersen had a greater likelihood of survival compared to those who received sham treatment.
The US FDA has approved the first drug for the treatment of spinal muscular atrophy, a genetic disease that often results in premature death.
Despite the benefits observed, the improvements still do not represent normal muscle function.
The study was the first to model the disease in a large animal with similar physiology to humans.
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- FDA Grants Orphan Drug Status to Angelman Syndrome Treatment
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Clinical, Radiologic Markers Predictive of Cortical Superficial Siderosis in ICH Identified
- Migraine Pain Location May Not Have Clinical Implications